Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Erlotinib has been shown to prolong progression‐free (PFS) and overall survival (OS) in
patients with advanced non‐small cell lung cancer (NSCLC). We report here on …

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …

Purpose To evaluate the efficacy of erlotinib, continued after tumor progression, plus
sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung …

Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

7033 Background: Erlotinib (E,[Tarceva]) is an orally available, reversible inhibitor of the
HER1/EGFR tyrosine kinase that has recently been approved by the FDA for the treatment of …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …

Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …